Drugs / TUB-040
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06303505 | Jun 2024 → Dec 2027 expected | non-small cell lung carcinoma, ovarian cancer | Tubulis GmbH | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-19 | Tubulis GmbH | Results Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025 tubulis.com ↗
Tubulis today announced positive early clinical data from its NAPISTAR1-01 Phase I/IIa study ( NCT06303505 ) in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. |
| 2024-06-27 | Tubulis GmbH | Regulatory Tubulis Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer tubulis.com ↗
Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the treatment of patients with platinum-resistant ovarian cancer. |
| 2024-04-08 | Tubulis GmbH | Results Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024 tubulis.com ↗
The poster presentations contained preclinical data, highlighting the ability of the two next-generation Tubutecan ADCs to create effective and durable responses even in low target-expressing tumor mouse models. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TUB-040 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06303505 ↗ |
| Route | Intravenous | “TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle” NCT06303505 ↗ |